Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-09-24
2010-12-07
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S183000
Reexamination Certificate
active
07846931
ABSTRACT:
The present invention provides compounds of formula Iand pharmaceutically acceptable salts thereof.The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
REFERENCES:
patent: 6670357 (2003-12-01), Leftheris et al.
patent: 6787545 (2004-09-01), Ohtani et al.
patent: 6867300 (2005-03-01), Godfrey, Jr. et al.
patent: 6869952 (2005-03-01), Bhide et al.
patent: 6908916 (2005-06-01), Mastalerz et al.
patent: 6916815 (2005-07-01), Vite et al.
patent: 6933386 (2005-08-01), Bhide et al.
patent: 6951859 (2005-10-01), Bhide et al.
patent: 6969717 (2005-11-01), Bhide et al.
patent: 6982265 (2006-01-01), Hunt et al.
patent: 7030118 (2006-04-01), Lombardo et al.
patent: 7064203 (2006-06-01), Gavai et al.
patent: 7102001 (2006-09-01), Swaminathan et al.
patent: 7102002 (2006-09-01), Cai et al.
patent: 7102003 (2006-09-01), Gavai et al.
patent: 7112675 (2006-09-01), Hunt et al.
patent: 7141571 (2006-11-01), Fink et al.
patent: 7151176 (2006-12-01), Gavai et al.
patent: 7244733 (2007-07-01), Hunt et al.
patent: 7297695 (2007-11-01), Fink et al.
patent: 7314876 (2008-01-01), Dyckman et al.
patent: 2004/0229877 (2004-11-01), Leftheris et al.
patent: 0 713 876 (1996-05-01), None
patent: WO 98/08847 (1998-03-01), None
patent: WO 00/71129 (2000-11-01), None
patent: WO 02/40486 (2002-05-01), None
patent: WO 03/042172 (2003-05-01), None
patent: WO 03/090912 (2003-11-01), None
patent: WO 2004/009784 (2004-01-01), None
patent: WO 2005/065266 (2005-07-01), None
Freshney et al.,Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4.
Dermer et al., Bio/Technology, 1994, 12:320.
Cohen et al., Current Opinion in Chemical Biology, 3,459-465, 1999.
Golub et al., Science, 286, 531-537, 1999.
Mass, R. D., Int. J. Radiation Oncology Bio. Phys.vol. 58(3): 932-940, 2004.
Ewald, H. et al., “Reaktionen von 1,2,4-Triazinen mit Acetylendicarbonsäure-dimethylester”, Liebigs Ann. Chem., pp. 1718-1724 (1977).
Hunt, J.T. et al., “Discovery of the Pyrrolo[2,1-f][1,2,4]triazine Nucleus as a New Kinase Inhibitor Template”, J. Med. Chem., vol. 47, No. 16, pp. 4054-4059 (2004).
Migliara, O. et al., “Synthesis of a New Bridgehead Nitrogen Heterocyclic System. Pyrrolo[2,1-f]-1,2,4-triazine Derivatives”, J. Heterocyclic Chem., vol. 16, pp. 833-834 (1979).
Tsi-Ping et al., TIPS 16: 5766, 1995.
Neunhoeffer, H. et al., “Cycloadditionen mit Methoxy- and Dialkylamino-1,2,4-triazinen”, Liebigs Ann. Chem., pp. 1413-1420 (1977).
Patil, S.A. et al., “Synthesis of Pyrrolo[2,1-f][1,2,4]triazine Congeners of Nucleic Acid Purines via theN-Amination of 2-Substituted Pyrroles”, J. Heterocyclic Chem., vol. 31, pp. 781-786 (1994).
Quintela, J.M. et al., “A Ready One-pot Preparation for Pyrrolo[2,1-f][1,2,4]triazine and Pyrazolo[5,1-c]pyrimido[4,5-e]-[1,2,4]triazine Derivatives”, Tetrahedron, vol. 52, No. 8, pp. 3037-3048 (1996).
Cecil Textbook of Medicine, vol. 1, pp. 1004-1010, 1996.
“A Comparison between BMS-690514 and Erlotinib in Patients who were previously treated for NSCLC”, www.clinicaltrials.gov; Identifier: NCT00743938 (Sep. 22, 2009).
“Phase I Study of BMS-690514 in Japanese Patients with Solid Tumors”, www.clinicaltrials.gov; Identifier: NCT00516451 (Oct. 10, 2008).
“A Phase I Study of BMS-690514 in Combination with Paclitaxel and Carboplatin”, www.clinicaltrials.gov; Identifier: NCT00420186 (Sep. 22, 2009).
“Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects”, www.clinicaltrials.gov; Identifier: NCT00578916 (Jul. 30, 2008).
“A Phase I Study of BMS-690514 in Patients with Advanced or Metastatic Solid Tumors”, www.clinicaltrials.gov; Identifier: NCT00329004 (Sep. 22, 2009).
“Combination Trial of BMS-690514 in Combination with FOLFIRI and FOLFOX”, www.clinicaltrials.gov; Identifier: NCT00479583 (Sep. 22, 2009).
Chen Ping
Fink Brian E.
Gavai Ashvinikumar V.
Han Wen-Ching
Mastalerz Harold
Balasubramanian Venkataraman
Bristol--Myers Squibb Company
Korsen Elliott
LandOfFree
Pyrrolotriazine compounds as kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolotriazine compounds as kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolotriazine compounds as kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4202222